anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity has emerged as a significant public health challenge. With the ongoing increase in life expectancy, the prevalence of obesity is steadily growing, particularly among older age demographics. The extension of life expectancy frequently results in additional years of vulnerability to chronic health issues associated with obesity in the elderly.The concept of SARS-CoV-2 directly infecting adipose tissue stems from the fact that both adipocytes and stromal vascular fraction cells express ACE2, the primary receptor facilitating SARS-CoV-2 entry. It is noteworthy that adipose tissue demonstrates ACE2 expression levels similar to those found in the lungs within the same individual. Additionally, ACE2 expression in the adipose tissue of obese individuals surpasses that in non-obese counterparts. Viral attachment to ACE2 has the potential to disturb the equilibrium of renin-angiotensin system homeostasis, leading to an exacerbated inflammatory response.Consequently, adipose tissue has been investigated as a potential site for active SARS-CoV-2 infection, suggesting its plausible role in virus persistence and contribution to both acute and long-term consequences associated with COVID-19.This review is dedicated to presenting current evidence concerning the presence of SARS-CoV-2 in the adipose tissue of elderly individuals infected with the virus. Both obesity and aging are circumstances that contribute to severe health challenges, heightening the risk of disease and mortality. We will particularly focus on examining the mechanisms implicated in the long-term consequences, with the intention of providing insights into potential strategies for mitigating the aftermath of the disease.
<P>PROBLEM TO BE SOLVED: To provide a sesame extract as a new food material, cosmetic, and medical material which have a component derived from a natural substance as an active ingredient, accordingly has no concern for safety, exhibits an excellent effect on the improvement of skin roughness and the prevention of skin aging, and furthermore shows a never-known-before effect on the skin or the cutis.  <P>SOLUTION: The sesame extract comprises, as active ingredients, sesame lignans of antioxidants, saturated fatty acids, unsaturated fatty acids, and enzymes which are derived from sesame seeds and present in sesame seeds as active ingredients. The sesame extract comprises not less than 0.9 wt.% sesamins in the extract of sesame seeds. The sesame extract is provided in the form of a sesame oil obtained by pressing sesame seeds at a low temperature of not higher than 30°C. The sesame extract is provided in the form of an extract of the sesame oil obtained by pressing sesame seeds at low temperatures.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Although the near-term benefit of immune tolerance induction (ITI) for the treatment of people with severe hemophilia A with inhibitor is apparent, the magnitude of the longer-term impact of ITI on clinical outcomes remains undefined. We examined the association between receiving ITI and the success of ITI on clinical outcomes including (1) clinical events, (2) health care use, (3) quality of life/function, (4) socioeconomic status, and (5) death, using the Community Counts (CC) registry of US Hemophilia Treatment Centers between 2013 and 2017. Multivariate logistic regression, negative binomial, and Poisson models were used. Included in this study were 3659 people with severe hemophilia A with median age of 21 years when entering the CC registry. Among 576 participants with inhibitors, 485 had received ITI (84%). ITI was successful in 299 (61.7%) and partially successful or failed in 95 (19.5%) or 91 (18.7%), respectively. Those that received ITI had fewer treated bleeds, less chronic pain, better function, and higher educational attainment than those not receiving ITI. Successful vs partially successful and failed ITI was associated with fewer treated bleeds, less health care use, less chronic pain, better function, and fewer missed days of school or work. Mortality was not associated with ITI, regardless of its success. Those with successful ITI had similar rates of treated bleeds, chronic pain, and health care use as those with no inhibitors. Undergoing ITI, particularly if successful, improved clinical outcomes but not mortality. These findings support decision making regarding initiation of ITI and inform future clinical trials.
Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
A device and method for radioembolization in the treatment of cancer cells in the body. In preferred embodiments, a radiomicrosphere is formed from a resin where an alpha emitting isotope is used for tumoricidal purposes. As the alpha emitter decays, daughters of the alpha decay are captured by the resin. In accordance with the preferred embodiments, the resin is polyfunctional where the resin has at least three different types of functional groups for cation binding. In preferred embodiments, the three functional groups bonded to the resin include a carboxylic acid group, a diphosphonic acid group, and a sulfonic acid group. In further embodiments, the device comprises at least two isotopes; wherein a first isotope is for therapeutic purposes and a second isotope is for dosimetric purposes. The second isotope is a positron emitter for PET based dosimetry. In preferred embodiments, a post-treatment radiation absorbed dose is determined using the present invention, allowing both treatment and treatment efficacy to be provided to a cancer patient.
Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
Psychiatric disturbances are commonly associated with adult-onset isolated dystonia (AOID); however, the mechanisms underlying psychiatric abnormalities in AOID remain unknown. We aimed to investigate the structural and functional brain changes in AOID patients with anxiety, and identify imaging biomarkers for diagnosing anxiety. Structural and functional magnetic resonance was performed on 69 AOID patients and 35 healthy controls (HCs). The Hamilton Anxiety Scale (HAMA) was used to assess anxiety symptoms in AOID patients and assign patients to AOID with and without anxiety groups. Group differences in grey matter volume, amplitude of low-frequency fluctuations (ALFF), fractional ALFF, and regional homogeneity (ReHo) were evaluated. Area under the receiver operating characteristic curve (ROC AUC) was used as a metric to identify imaging biomarkers for diagnosing anxiety. AOID patients with anxiety exhibited an increased ALFF and ReHo in the left angular gyrus (ANG.L) compared with those without and HCs (voxel P<0.001 and cluster P<0.05, corrected using GRF). A significant positive correlation was observed between ALFF (r = 0.627, P<0.001) and ReHo (r = 0.515, P<0.001) in the ANG.L and HAMA scores in AOID patients. ALFF and ReHo in the ANG.L exhibited an ROC AUC of 0.904 and 0.851, respectively, in distinguishing AOID patients with anxiety from those without and an ROC AUC of 0.887 and 0.853, respectively, in distinguishing AOID patients with anxiety from HCs. These findings provide new insights into the pathophysiology of psychiatric disturbances and highlight potential candidate biomarkers for identifying anxiety in AOID patients.
BACKGROUND: Despite advances in clinical management, cytomegalovirus (CMV) infection remains a serious complication and an important cause of morbidity and mortality following kidney transplantation. Here, we explore the importance of viral load kinetics as predictors of risk and potential guides to therapy to reduce transplant failure in a large longitudinal Genome Canada Transplant Consortium (GCTC) kidney transplant cohort.
METHODS: We examined the relationship between CMV infection rates and clinical characteristics, CMV viral load kinetics, and graft and patient outcomes in 2510 sequential kidney transplant recipients in the British Columbia Transplant Program. Transplants were performed between January 1, 2008, and December 31, 2018, were managed according to a standard protocol, and were followed until December 31, 2019, representing over 3.4 million days of care.
RESULTS: Longitudinal CMV testing was performed in 2464 patients, of whom 434 (17.6%) developed a first episode of CMV viremia at a median of 120 (range: 9-3906) days post-transplant. Of these patients, 93 (21.4%) had CMV viremia only and 341 (78.6%) had CMV viremia with clinical complications, of whom 21 (4.8%) had resulting hospitalization. A total of 279 (11.3%) patients died and 177 (7.2%) patients lost their graft during the 12 years of follow-up. Patients with CMV infection were at significantly greater risk of graft loss (p=0.0041) and death (p=0.0056) than those without. Peak viral load ranged from 2.9 to 7.0 (median: 3.5) log10 IU/mL, the duration of viremia from 2 to 100 (15) days, and the viral load area under the curve from 9.4 to 579.8 (59.7) log10 IU/mL × days. All three parameters were closely inter-related and were significantly increased in patients with more severe clinical disease or with graft loss (p=0.001). Duration of the first CMV viremic episode greater than 15 days or a peak viral load ≥4.0 log10 IU/mL offered simple predictors of clinical risk with a 3-fold risk of transplant failure.
CONCLUSION: Viral load kinetics are closely related to CMV severity and to graft loss following kidney transplantation and provide a simple index of risk which may be valuable in guiding trials and treatment to prevent transplant failure.
The invention relates to an andrographolide dispersible tablet prepared in a pellet tableting process. The andrographolide dispersible tablet is characterized in that the tablet is composed of an andrographolide pellet and a blank pellet tablet, and the mass ratio of the andrographolide pellet to the blank pellet tablet is 1:0.75-1:1.05. The andrographolide pellet is composed of andrographolide, filler, an adhesion agent, corrigent and a disintegrating agent. An extrusion rolling method is used for preparing a pellet core containing medicine, and then a fluidized bed coating technology is used for enabling the pellet core to be coated with a polyving akohol-polyethylene glycol copolymer to form the andrographolide pellet. The blank pellet tablet is composed of filler, an adhesion agent, a disintegrating agent and a coloring agent, and an extrusion rolling method is used for preparing the blank pellet tablet. The andrographolide pellet and the blank pellet tablet are pressed to be tablet after being mixed evenly in proportion, and the andrographolide dispersible tablet can be obtained. The andrographolide dispersible tablet is quick, effective, safe, free of discomfortable bitter taste, and flexible in dosage.
OBJECTIVE: To define the incidence and risk factors for developing chemotherapy-induced neuropathic pain (CINP).
METHODS: Retrospective, file-based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy-induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI-NRS and Douleur Neuropathique-4 questionnaire. The total neuropathy score-clinical version graded the severity of CIPN.
RESULTS: The medical files of 500 chemotherapy-treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2-3 chronic CIPN (OR: 1.61; p < .001) as also the administration of combined paclitaxel plus cisplatin (reference variable), compared to oxaliplatin (OR: 0.18; p = .001) and taxanes (OR: 0.16; p < .001). The increased severity of acute OXAIPN was associated with CINP (OR: 4.51; p < .001). OXA-treated patients with persistent CINP presented a worst likelihood to improve after chemotherapy discontinuation, than patients receiving combined paclitaxel plus cisplatin (OR: 50; p < .001).
CONCLUSION: The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post-chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA-treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.
PROBLEM TO BE SOLVED: To obtain an antiseptic microbicide which can reduce the amount of paraben used by increasing the antimicrobial potency of paraben, and possesses high safety by using at least one kind of specific three kinds of 1,2- alkanediols and paraben in combination. SOLUTION: This antiseptic microbicide is composed of the combination of (A) at least one kind of parabens of the formula (R is a 1-4C alkyl) and (B) at least one kind selected from 1,2-pentanediol, 1,2-hexanediol or 1,2- octanediol. When this antiseptic microbicide is blended as an antiseptic microbicide for cosmetics for skin and hair, e.g. toilet water, milky lotion, cream and the like, the cosmetic composition having high safety and efficient antimicrobial activity can be obtained. In this case, it is favorable that the combination amount of methyl paraben in the composition is less than 0.2 wt.%. Further, the component B is preferably blended in a proportion of 0.05-20 wt.% in this composition. As a result, a cosmetic having reduced irritation to skin can be provided.
This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
This group will incorporate the standard of care physical therapy regimen which includes a specific and structured combination of quadriceps and gluteal strengthening as defined in the patellofemoral pain clinical practice guideline. Typical structured/skilled physical therapy occurs over the course of 4-8 weeks with 1-2 visits per week to establish improved lower extremity muscle strength, education, and improve gross function. Home exercise programs (HEP) are utilized in tandem with physical therapy visits so that patients are completing interventions 4-5 days per week. Long-term maintenance is generally provided via a refined comprehensive HEP on completion and discharge from formal physical therapy.
Derivatives of 7-aminocephalosporanic acid have the formula <FORM:1066347/C2/1> in which A1 and A2 each are aliphatic hydrocarbon of up to 6 carbon atoms, which may be substituted by halogen and alkoxy of 1 to 5 carbon atoms.  The compounds are prepared by reacting a desacetyl-7-amino-cephalosporanic acid of formula <FORM:1066347/C2/2> in which R is H or CO-NH-A1 with an isocyanic acid ester of formula A2-N = C = O, and, if desired, converting the resulting compound into a salt.  Salts may be alkali metal, alkaline earth or organic base salts.  The halogen atoms are preferably in the beta position to the carbamyl group.  A typical compound is 3-desacetyl - 3 - (beta - chloroethylcarbamoyl) - 7 - (beta-chloroethyl ureido)-cephalosporanic acid.  Pharmaceutical formulations for internal or external use comprise a compound as in Formula I above and/or a salt thereof with a carrier.  Tablets, dragees, ointments, creams, capsules, solutions, suspensions and emulsions are typical formulations. The active ingredients are broad spectrum antibiotics and are effective against penicillin-resistant strains of micro-organisms.
Safety and effectiveness in pediatric patients with major depressive disorder or agitation associated with schizophrenia or bipolar mania have not been established.

Safety and effectiveness in pediatric patients with schizophrenia were established in a 6-week, placebo-controlled clinical trial in 202 pediatric patients aged 13 to 17 years [see INDICATIONS AND USAGE (1.1), DOSAGE AND ADMINISTRATION (2.1), ADVERSE REACTIONS (6.2), and CLINICAL STUDIES (14.1)]. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients. 

Safety and effectiveness in pediatric patients with bipolar mania were established in a 4-week, placebo-controlled clinical trial in 197 pediatric patients aged 10 to 17 years [see INDICATIONS AND USAGE (1.2), DOSAGE AND ADMINISTRATION (2.2), ADVERSE REACTIONS (6.2), and CLINICAL STUDIES (14.2)]. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

The efficacy of adjunctive ABILIFY with concomitant lithium or valproate in the treatment of manic or mixed episodes in pediatric patients has not been systematically evaluated. However, such efficacy and lack of pharmacokinetic interaction between aripiprazole and lithium or valproate can be extrapolated from adult data, along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two 8 week, placebo-controlled clinical trials in 212 pediatric patients aged 6 to 17 years [see INDICATIONS AND USAGE (1.4),  DOSAGE AND ADMINISTRATION (2.4),  ADVERSE REACTIONS (6.2), and  CLINICAL STUDIES (14.4)]. Maintenance efficacy in pediatric patients has not been systematically evaluated.

The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
PROBLEM TO BE SOLVED: To obtain a massage cosmetic having excellent immunopotentiating actions by using a specific wax with a specified hydroxy-fatty acid in combination. SOLUTION: This immunopotentiating massage cosmetic is obtained by combining a high-melting wax with a 12-22C hydroxy-fatty acid. The content of an ingredient which is a solid at normal temperatures other than the high- melting wax and the 12-22C hydroxy-fatty acid is preferably 1-15wt.% in the massage cosmetic. A high-melting wax having >=60 and <=110 deg.C melting point is preferred as the high-melting wax and carnauba wax, Japan wax, spermaceti, beeswax, etc., are especially cited. A hydroxy-stearic acid is preferred as the hydroxy-fatty acid. The content of the high-melting wax is 5-20wt.% and that of the fatty acid is 0.1-5wt.%. The dosage form is preferably an oil gel one.
PURPOSE: Lung fibrosis is a heterogeneous lung condition characterized by excessive accumulation of scarred tissue, leading to lung architecture destruction and restricted ventilation. The current work was conducted to examine the probable shielding influence of cinnamic acid against lung fibrosis induced by methotrexate.
METHODS: Rats were pre-treated with oral administration of cinnamic acid (50 mg/kg/day) for 14 days, whereas methotrexate (14 mg/kg) was orally given on the 5th and 12th days of the experiment. Pirfenidone (50 mg/kg/day) was used as a standard drug. At the end of the experiment, oxidative parameters (malondialdehyde, myeloperoxidase, nitric oxide, and total glutathione) and inflammatory mediators (tumor necrosis factor-α and interleukin-8), as well as transforming growth factor-β and collagen content, as fibrosis indicators, were measured in lung tissue.
RESULTS: Our results revealed that cinnamic acid, as pirfenidone, effectively prevented the methotrexate-induced overt histopathological damage. This was associated with parallel improvements in oxidative, inflammatory, and fibrotic parameters measured. The outcomes of cinnamic acid administration were more or less the same as those of pirfenidone. In conclusion, pre-treatment with cinnamic acid protects against methotrexate-induced fibrosis, making it a promising prophylactic adjuvant therapy to methotrexate and protecting against its possible induction of lung fibrosis.
Participants will be administered HFB200603 in combination with tislelizumab at combination RDEs as an intravenous infusion. Based on the cancer type, participants will be randomized to combination HFB200603 RDE 1 or RDE 2.
Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
The underlying contribution of immune complexes in modulating adaptive immunity in mucosal tissues remains poorly understood. In this report, we examined, in mice, the proinflammatory response elicited by intranasal delivery of the biothreat agent ricin toxin (RT) in association with two toxin-neutralizing mAbs, SylH3 and PB10. We previously demonstrated that ricin-immune complexes (RICs) induce the rapid onset of high-titer toxin-neutralizing Abs that persist for months. We now demonstrate that such responses are dependent on CD4+ T cell help, because treatment of mice with an anti-CD4 mAb abrogated the onset of RT-specific Abs following intranasal RICs exposure. To define the inflammatory environment associated with RIC exposure, we collected bronchoalveolar lavage fluid (BALF) and sera from mice 6, 12, and 18 h after they had received RT or RICs by the intranasal route. A 32-plex cytometric bead array revealed an inflammatory profile elicited by RT that was dominated by IL-6 (>1500-fold increase in BALF) and secondarily by KC (CXCL1), G-CSF, GM-CSF, and MCP-1. RICs induced inflammatory profiles in both BALF and serum response that were similar to RT, albeit at markedly reduced levels. These results demonstrate that RICs retain the capacity to induce local and systemic inflammatory cytokines/chemokines that, in turn, may influence Ag sampling and presentation in the lung mucosa and draining lymph nodes. A better understanding of the fate of immune complexes following intranasal delivery has implications for the development of mucosal vaccines for biothreats and emerging infectious diseases.
Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.